SCM LIFESCIENCE
For a better future SCM Lifescience will do its best
History
SCM Lifescience,
It contains the best technology and passion.

2008 - present

2021
2021
  • 07

    US patent registration for pharmaceutical composition for the prevention or treatment of regulatory T cell-mediated diseases

    Signed a contract to introduce a license for diabetes treatment with Allial Biotechnology & Pharmaceuticals in the USA

  • 06

    Registered a domestic patent for a composition for enhancing the function of stem cells

    Equity investment in Vita Therapeutics, USA

  • 05

    Registered a domestic patent for a pharmaceutical composition for the treatment of graft-versus-host disease containing clonal stem cells

    Chinese patent registration of stem cell-derived hair loss prevention composition

  • 04

    Registered a domestic patent for a pharmaceutical composition for the treatment of pancreatitis containing clonal stem cells

  • 03

    Application for approval (IND) for domestic phase 2 clinical trial for the treatment of polyQ spinocerebellar ataxia

    Acquired high-tech biopharmaceutical manufacturing license

    SCM Lifescience and CHA Biotech signed a contract for the consignment production (CMO) of bone marrow-derived cell therapy products

    Selected as a 'Global IP (Intellectual Property) Star Enterprise Promotion Project'

  • 01

    Australian patent registration for pharmaceutical composition for the prevention or treatment of regulatory T cell-mediated diseases

2020
  • 12

    Japanese patent registration for next-generation stem cell isolation and culture method

    Official invitation to JPMorgan Healthcare Conference.

  • 10

    Approval of orphan drug designation in domestic development stage for acute pancreatitis treatment (SCM-AGH)

    A contract to introduce a domestic exclusive license for stem cell therapy for spinal cerebrosclerosis was signed.

    The Ministry of Food and Drug Safety designates a rare drug for acute pancreatitis treatment.

    Taiwan’s Steminent Biotherapeutics signs a contract to introduce an exclusive domestic license for Stemchymal, a stem cell treatment for spinal cerebellar ataxia

    Completed phase 1 clinical trial for atopic dermatitis treatment

  • 09

    SCM Lifescience and Pharmimex JSC, stem cell technology license out MOU

  • 08

    SCM Lifescience-TheraImmune, start developing cell therapy for autoimmune diseases

    SCM Lifescience-PBS Biotech mass-produced stem cell therapy

  • 06

    Listed on KOSDAQ

  • 04

    Acquired and merged with Coimune, an American corporation, and Formulaa, Italy

  • 03

    SCM Lifescience and Inha University Hospital sign a business agreement to develop a treatment for COVID-19

  • 02

    Co-Immune, a U.S. corporation, approved by the U.S. FDA for a phase 2b clinical trial plan for a dendritic cell treatment vaccine for metastatic renal cancer

2019
  • 11

    Awarded the Ministry of Science, Technology and Information and Communication Award for Contribution to Research Industry

  • 07

    Signed MOU with SCM Lifescience and Mitoimmune Therapeutics to develop new drugs for rare diseases

  • 06

    Announcement of designation of SCM-CGH (injection) as 'orphan drug in development stage' (Ministry of Food and Drug Safety Announcement No. 2019 - 278)

    SCM Lifescience-Handok equity investment and signing a license out contract for stem cell treatment for severe atopic dermatitis

    Signed MOU with SCM Lifescience and T&R Biofab for joint development of 3D bioprinting graft treatment

    SCM Lifescience and Ilya Biologics signed an MOU for joint development of high-purity mesenchymal stem cell-derived exosomes

  • 05

    Signed MOU for joint research on next-generation cell therapy products and biomarkers with SCM Lifescience and Syntekabio

  • 04

    KFDA Approval for Extended Clinical Trial for Long-Term Safety Follow-up of SCM-AGH in Patients with Severe Acute Pancreatitis

  • 02

    Awarded the Minister of Food and Drug Safety Award at the 2019 Annual General Meeting of the Korea Biopharmaceutical Association

2018
  • 11

    Foreign investment attraction, CCM Duopharma

  • 10

    SCM Lifescience and University of Utah joint research agreement for stem cell therapy using cell sheet

  • 08

    Attracting 3rd investment from investment institutions

  • 06

    Signed MOU with SCM Lifescience and Toolgen to develop gene-inserted stem cell therapy

  • 05

    Received the Minister of Health and Welfare Award for Meritorious Person in the Health Industry, Song Soon-wook, Executive Vice President

  • 04

    BG Rhee inaugurated as new CEO

  • 03

    Approval of phase 1,2a clinical trial for acute pancreatitis 'SCM-AGH'

  • 01

    Acquired a patent for next-generation stem cell manufacturing technology specializing in immune diseases

2017
  • 11

    Approval of phase 2 clinical trial for acute graft-versus-host disease 'SCM-AGH'

  • 06

    High-purity stem cell isolation and culture method certified as a new health technology (NET)

  • 03

    Identification of the mechanism of action for the treatment of immune diseases through mesenchymal mesenchymal cells (MSCs, adult stem cells) for the first time in the world

  • 01

    Acquired ISO 9001:2015 certification

    Signed MOU contract with SCM Lifescience for joint development of MDimmune atopic treatment

2016
  • 03

    Approval of the graft-versus-host disease clinical trial (Phase 2)

  • 02

    Attracting secondary investment from investment institutions

2015
  • 12

    Presentation of a paper on manufacturing high-purity stem cell therapeutics

  • 10

    US MESA invited lecture

  • 03

    Attracting the first investment from investment institutions

  • 01

    Japanese patent registration for graft-versus-host disease treatment technology

2014
  • 10

    Establishment of research institute affiliated with SCM Lifescience Co., Ltd.

  • 08

    Registered US patent for manufacturing method of high-purity stem cell therapy

  • 07

    European Union patent registration for high-purity stem cell isolation technology

    Sun U. Song inaugurated as CEO

    Established SCM Lifescience Co., Ltd.

2013
  • 01

    Patent registration for high-purity adult stem cell isolation technology in China

2012
  • 12

    Registered Japanese patent for high-purity adult stem cell isolation technology

    Patent application for manufacturing method of high-purity stem cell therapy

  • 06

    Graft-versus-host disease clinical trial (Phase 1) completed

2011
  • 12

    Patent application for treatment of acute pancreatitis using high-purity mesenchymal stem cells

  • 11

    Patent application for spinal cord injury treatment using high-purity mesenchymal stem cells

2010
  • 10

    Started graft-versus-host disease clinical trial (Phase 1)

  • 08

    Acquired US patent for high-purity adult stem cell isolation technology

2008
  • 01

    Registered a Korean patent for high-purity adult stem cell isolation technology